CLINICAL MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Edited by

Thomas Similowski
Groupe Hospitalier Pitie'-Salpe'triere
Paris, France

William A. Whitelaw
University of Calgary
Calgary, Alberta, Canada

Jean-Philippe Derenne
Groupe Hospitalier Pitie'-Salpe'triere
Paris, France
**CONTENTS**

<table>
<thead>
<tr>
<th>Introduction</th>
<th>Claude Lenfant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface</td>
<td>v</td>
</tr>
<tr>
<td>Contributors</td>
<td>ix</td>
</tr>
<tr>
<td>Foreword</td>
<td>Gordon L. Snider xxix</td>
</tr>
</tbody>
</table>

**Part One  DIAGNOSIS AND FOLLOW-UP**

1. **The Lung in Transition from Health to Disease**
   *Manuel G. Cosio, David H. Eidelman, and James G. Martin*
   
   I. Introduction
   II. Age-Related Decline in Lung Function
   III. Detection Techniques for the Assessment of Early Altered Lung Function
   IV. Structure-Function Correlations for Tests Based on Small Airways Dysfunction
   V. Airway Inflammatory Responses to Irritants
   VI. Biochemical Markers of Early Lung Inflammation in Smokers
   VII. Differences in Airway Inflammation Between Smokers with and Without COPD

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>1</td>
</tr>
<tr>
<td>II</td>
<td>2</td>
</tr>
<tr>
<td>III</td>
<td>4</td>
</tr>
<tr>
<td>IV</td>
<td>7</td>
</tr>
<tr>
<td>V</td>
<td>8</td>
</tr>
<tr>
<td>VI</td>
<td>8</td>
</tr>
<tr>
<td>VII</td>
<td>9</td>
</tr>
</tbody>
</table>
VIII. Heterogeneity in the Patterns of Lung Damage in Smokers 12
IX. Risk Factors for the Development of COPD 13
X. The Tip of the Iceberg 16
XI. Conclusions 17
References 17

2. Clinical Examination in Clinical Obstructive Pulmonary Disease and Correlation with Functional Abnormalities 23
   Robert G. Badgett and David Tanaka
   I. What Are the Best Findings to Diagnose COPD 23
   II. How Well Does History and Physical Examination Diagnose COPD? 27
   III. Summary 29
   References 32

3. Technique and Interpretation of Blood Gases in Stable Chronic Obstructive Pulmonary Disease 35
   Alain Harf
   I. Blood Gases: Techniques of Evaluation 35
   II. Blood Gases: Interpretation 43
   References 49

4. Basic Spirometry in COPD 53
   Marc Zelter
   I. Introduction 53
   II. Assessment of Flow Limitation in COPD 54
   III. Lung Volume Measurements 59
   IV. Reference Values for Flows and Volumes 61
   V. Bronchial Hyperreactivity Testing 62
   VI. How Often Should Lung Function Be Assessed? 63
   VII. Conclusion 63
   References 63

5. Imaging Techniques of the Thorax in Stable Chronic Obstructive Pulmonary Disease Patients 69
   Philippe Grenier and Catherine Beigelman
   I. Introduction 69
   II. Radiographic Manifestations 70
   III. CT Manifestations 75
   IV. CT Quantification of Emphysema 82
   V. Nuclear Medicine 85
   VI. Magnetic Resonance Imaging 85
   References 88
6. Diagnosis, Initial Assessment, and Follow-Up of COPD  
*Paul A. Vermeire*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>95</td>
</tr>
<tr>
<td>II. Diagnosis</td>
<td>95</td>
</tr>
<tr>
<td>III. Needs and Objectives of the Initial Assessment After First Diagnosis</td>
<td>96</td>
</tr>
<tr>
<td>IV. Components of Initial Assessment After Diagnosis of COPD</td>
<td>97</td>
</tr>
<tr>
<td>V. Follow-Up</td>
<td>107</td>
</tr>
<tr>
<td>VI. Concluding Remarks</td>
<td>109</td>
</tr>
<tr>
<td>References</td>
<td>109</td>
</tr>
</tbody>
</table>

7. Assessment and Management of Dyspnea in Chronic Obstructive Pulmonary Disease  
*Denis E. O'Donnell*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>113</td>
</tr>
<tr>
<td>II. Mechanisms of Dyspnea in COPD</td>
<td>114</td>
</tr>
<tr>
<td>III. Assessment of Dyspnea</td>
<td>122</td>
</tr>
<tr>
<td>IV. Management of Dyspnea in Advanced COPD</td>
<td>132</td>
</tr>
<tr>
<td>V. Experimental Approaches to Dyspnea Management</td>
<td>152</td>
</tr>
<tr>
<td>VI. Summary</td>
<td>157</td>
</tr>
<tr>
<td>References</td>
<td>158</td>
</tr>
</tbody>
</table>

8. The Assessment of Health-Related Quality of Life Among Patients with Chronic Obstructive Pulmonary Disease  
*David H. Au, J. Randall Curtis, and Leonard D. Hudson*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>171</td>
</tr>
<tr>
<td>II. Terms and Definitions</td>
<td>172</td>
</tr>
<tr>
<td>III. Relevance and Use of Health-Related Quality of Life</td>
<td>175</td>
</tr>
<tr>
<td>IV. Generic Versus Disease Specific Instruments</td>
<td>176</td>
</tr>
<tr>
<td>V. Generic Health-Related Quality-of-Life Instruments in COPD</td>
<td>176</td>
</tr>
<tr>
<td>VI. Disease-Specific Measurements in COPD</td>
<td>179</td>
</tr>
<tr>
<td>VII. Future Directions</td>
<td>181</td>
</tr>
<tr>
<td>VIII. Summary</td>
<td>181</td>
</tr>
<tr>
<td>References</td>
<td>182</td>
</tr>
</tbody>
</table>

9. Disability in Chronic Obstructive Pulmonary Disease  
*Abebaw M. Yohannes and Martin J. Connolly*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>187</td>
</tr>
<tr>
<td>II. Impairment, Disability and Handicap</td>
<td>188</td>
</tr>
<tr>
<td>III. Severity of Disease</td>
<td>189</td>
</tr>
<tr>
<td>IV. Social Care Support and Disabling COPD</td>
<td>191</td>
</tr>
</tbody>
</table>
10. The General Practitioner and the Chronic Obstructive Pulmonary Disease Patient

C. P. van Schayck, P. M. van Grunsven, C. van Weel, and G. van den Boom

I. Introduction 201
II. Pathophysiology 202
III. Treatment of COPD with Inhaled Corticosteroids 203
IV. Treatment of COPD with N-Acetylcysteine 206
V. Nondrug Treatment Options 207
VI. Management of COPD in Primary Care 207
VII. Aims of Treatment 209
VIII. Treatment Strategy 210
IX. Summary 215
References 215

Part Two  PATHOPHYSIOLOGICAL TREATMENTS

11. Genetics of Chronic Obstructive Pulmonary Disease and Emphysema: Diagnostic Applications and Therapeutic Perspectives

Andrew J. Sandford and Peter D. Pare

I. Introduction 221
II. Genetic Epidemiology of COPD 221
III. Identification of Susceptibility Genes 222
IV. Genes Involved in the Pathogenesis of COPD 224
V. Proteolysis-Antiproteolysis 226
VI. Inflammatory Mediators 229
VII. Xenobiotic Metabolizing Enzymes 230
VIII. Cystic Fibrosis Transmembrane Regulator 232
IX. Diagnostic and Therapeutic Implications of COPD Genetics 233
X. Conclusions 234
References 235

12. Is There a Place or a Future for Antioxidant Therapy in COPD?

Bruno Housset and Bernard Maitre

I. Nature of Oxygen-Derived Metabolites 245
Contents

II. Toxic Effects of Oxygen-Derived Metabolites 246
III. Antioxidants 247
IV. COPD and Oxidant Burden 248
V. Antioxidant Therapy in COPD 249
References 251

Part Three PHARMACOLOGICAL THERAPY

13. Methodology of Therapeutic Trials in COPD 255
   Yves Lacasse and Gordon H. Guyatt

   I. Introduction 255
   II. Study Population: What is COPD? 256
   III. Intervention 259
   IV. Outcomes 259
   V. Design 261
   VI. Analysis and Interpretation 265
   VII. Overviews and Meta-Analyses 276
   VIII. Conclusion 278
   References 278

14. Beta₂-Adrenergic Bronchodilators in the Treatment of Stable COPD 287
   Michael L. Ayers and Donald A. Mahler

   I. Introduction 287
   II. Pharmacology and Pharmacokinetics 288
   III. Administration 289
   IV. Goals of Therapy 289
   V. Is Testing for Acute Bronchodilator Responsiveness Useful? 290
   VI. Short-Acting pYAgonists 291
   VII. Long-Acting pVAgonists 293
   VIII. Side Effects 299
   IX. For Which COPD Patients Should Long-Acting P₂-Adrenergic Agonists Be Prescribed? 300
   References 301

15. The Indications and Use of Inhaled Anticholinergic Agents in COPD Patients 305
   Stephen Come and N. Anthonisen

   I. Introduction 305
   II. Cholinergic Receptors in the Lung 306
   III. Pharmacology 307
   IV. Safety and Side Effects 308
V. Effects on Mucociliary Clearance
VI. Dose Response
VII. Comparison of Bronchodilator Response of Anticholinergics With (3-Agonists in COPD
VIII. Combination Therapy: Is There a Rationale for Its Use?
IX. Do Anticholinergics Improve Symptoms and Quality of Life in COPD?
X. Method of Delivery: Nebulizer vs. MDI
References

16. Steroids in Stable COPD
J. C. Yernault
I. Acute Exacerbations
II. Short-Term (3 Month) Effects of Oral (Alone, or Compared to Inhaled) Steroids in Stable COPD
III. Long-Term Effects of Oral Steroids in Stable COPD
IV. Short-Term (<3 Months) Effects of Inhaled Steroids in Stable COPD
V. Long-Term Effects of Inhaled Steroids in Stable COPD
VI. Conclusion
Addendum
References

17. Is There a Place for Vasodilators in Stable COPD?
George Cremona and Tim Higenbottam
I. Introduction
II. Anatomical Changes in the Pulmonary Vascular Bed Associated with Chronic Obstructive Airways Disease
III. Pulmonary Hemodynamics in Stable COPD Patients
IV. Gas Exchange in Stable COPD Patients
V. Pathophysiology of Chronic Hypoxic Pulmonary Hypertension
VI. Rationale for Vasodilator Therapy in Stable COPD Patients
VII. Conclusion
References

18. Is There a Place for Respiratory Analeptics or Related Drugs in Stable COPD Patients?
Roberto Duranti, Giorgio Scano, and Nicolino Ambrosino
I. Introduction
II. Almintrine Bismesylate
III. Analeptics
IV. Narcotic Antagonists 390
V. Progestational Hormones 390
VI. Carbonic Anhydrase Inhibitors 392
VII. Tricyclic Antidepressants 393
VIII. Theophyllines 395
IX. Conclusion 395
References 396

19. Should Drugs Affecting Mucus Properties Be Used in COPD? 405
Clinical Evidence
Julia A. Nightingale and Duncan F. Rogers

I. Introduction 405
II. Mucolytics 409
III. Mucoregulators ("Blocked" Sulfhydryl Group) 411
IV. Expectorants 413
V. Muscarinic Receptor Antagonists (Anticholinergics) 415
VI. Recombinant Human DNase 415
VII. Corticosteroids 416
VIII. Erythromycin 417
IX. Summary and Conclusions 417
References 417

Part Four TREATMENT AND PREVENTION OF INFECTION

20. Indications for and Choice of Antibiotics in COPD 427
S. Ewig, R. Rodriguez-Roisin, and A. Torres

I. Introduction 427
II. Colonization of Stable COPD Patients 428
III. Role of Bacteria and Viruses in COPD Exacerbations 432
IV. Predictors of Particular Microorganisms 436
V. Antibiotics in COPD 437
VI. Conclusions 444
References 444

Part Five ASSOCIATED DISEASES AND THEIR THERAPY

21. The Diagnosis and Management of Lung Cancer in COPD 451
V. Ninane, T. Berghmans, and J. -P. Sculier

I. Epidemiological Data 451
II. Early Detection 454
III. Treatment 455
IV. Elective Chest Irradiation of Limited Non-Small Cell Lung Cancer 460
V. Endoscopic Palliation of Central Airway Obstruction 465
VI. Chemotherapy for Advanced Non-Small Cell Lung Cancer 465
VII. Treatment of Small Cell Lung Cancer 466
References 466

22. The Heart in the Stable COPD Patient 475
Teofilo L. Lee-Chiong, Jr., and Richard A. Matthay

I. Introduction 475
II. Incidence 475
III. The Pulmonary Circulation in COPD 476
IV. The Right Ventricle in COPD 478
V. The Left Ventricle in COPD 481
VI. Etiology of Pulmonary Artery Hypertension in COPD 482
VII. Natural History of Untreated Cor Pulmonale 485
VIII. Prognosis of Patients with Cor Pulmonale 486
IX. Cardiac Arrhythmia in Patients with COPD 487
X. Edema Formation in COPD 490
XL Evaluating Cardiac Function in Patients with COPD 493
XII. Therapy for Cor Pulmonale Secondary to COPD 500
XIII. Conclusion 514
Acknowledgments 515
References 515

23. COPD and the Left Heart 533
Teofilo L. Lee-Chiong, Jr., and Richard A. Matthay

I. Introduction 533
II. Left Ventricular Dysfunction in COPD 534
III. Normal Left Ventricular Performance in COPD 536
IV. Mechanisms of Left Ventricular Dysfunction in COPD 537
V. Effects of Medications on Left Ventricular Performance and Lung Function in COPD 540
VI. Summary 543
Acknowledgment 543
References 544

24. Anxiety and Depression in COPD 549
Noemi Eiser

I. Introduction 549
II. Depression 550
III. Anxiety and Panic 554
IV. Chronic Obstructive Pulmonary Disease 558
V. Prevalence of Anxiety and Depression in Patients with COPD 562
VI. Effects of Treatment of Mood Disorders in COPD Patient 564
Contents

VII. Incorporation of Psychological Therapy into Pulmonary Rehabilitation 570
VIII. Summary and Conclusions 571
References 573

25. Sleep-Related Respiratory Disorders in COPD: When and How to Make the Diagnosis 583
Isabelle Arnulf, Jean-Philippe Derenne, and William A. Whitelaw

I. Introduction 583
II. Methods of Investigations of Sleep-Related Respiratory Disorders in COPD 584
III. Night Sleep-Related Respiratory Phenomena 585
IV. Pathophysiology 588
V. Consequences 590
VI. When and How to Evaluate Sleep In COPD 594
References 596

26. Sleep-Related Respiratory Disorders in COPD: Who and How to Treat 603
Ana C. Krieger and David M. Rapoport and Patrick Levy

I. Introduction 603
II. Mechanisms 604
III. Who to Study 606
IV. How to Treat 609
V. Final Remarks 614
VI. Conclusions 614
References 614

Part Six RESPIRATORY MUSCLES, NUTRITION AND PHYSIOTHERAPY

27. The Relevance of Respiratory Muscles in COPD Patients and How to Assess Their Function 621
G. Czaika, A. Grassino, and P. Begin

I. Introduction 621
II. Factors Leading to Respiratory Muscle Dysfunction 622
III. Methods for Evaluating Respiratory Muscle Function 629
References 632

28. Corticosteroids and Muscle Function in Stable COPD 639
Ghislaine Gayan-Ramirez and Marc Decramer

I. Introduction 639
II. Studies In Experimental Animals 640
### Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>III. Studies In Patients</td>
<td>643</td>
</tr>
<tr>
<td>IV. Potential Mechanisms of Steroid-Induced Myopathy</td>
<td>650</td>
</tr>
<tr>
<td>V. Diagnosis and Therapy of Steroid-Induced Myopathy</td>
<td>652</td>
</tr>
<tr>
<td>VI. Conclusions</td>
<td>654</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>654</td>
</tr>
<tr>
<td>References</td>
<td>654</td>
</tr>
<tr>
<td>29. Pharmacotherapy and Hormone Therapy of the Respiratory Muscles in Stable COPD</td>
<td>659</td>
</tr>
<tr>
<td><em>Michael I. Polkey and John Moxham</em></td>
<td></td>
</tr>
<tr>
<td>I. General Rationale for Pharmacotherapy and Hormone Therapy</td>
<td>659</td>
</tr>
<tr>
<td>II. Discussion of Specific Agents</td>
<td>666</td>
</tr>
<tr>
<td>III. Conclusion</td>
<td>674</td>
</tr>
<tr>
<td>References</td>
<td>674</td>
</tr>
<tr>
<td>30. Nutritional Assessment and Support of the Stable COPD Patient</td>
<td>681</td>
</tr>
<tr>
<td><em>A. M. W. J. Schols and E. F. M. Wouters</em></td>
<td></td>
</tr>
<tr>
<td>I. Rationale for Nutritional Support</td>
<td>682</td>
</tr>
<tr>
<td>II. Body Composition</td>
<td>684</td>
</tr>
<tr>
<td>III. Causes of Weight Loss and Muscle Wasting</td>
<td>686</td>
</tr>
<tr>
<td>IV. Assessment of Energy Balance</td>
<td>689</td>
</tr>
<tr>
<td>V. Outcome of Nutritional Intervention</td>
<td>690</td>
</tr>
<tr>
<td>VI. Timing of Nutritional Support</td>
<td>691</td>
</tr>
<tr>
<td>VII. Macronutrient Composition of Nutritional Supplement</td>
<td>692</td>
</tr>
<tr>
<td>VIII. Practical Implementation of Nutritional Support</td>
<td>696</td>
</tr>
<tr>
<td>References</td>
<td>696</td>
</tr>
<tr>
<td>31. Respiratory Physiotherapy in Stable COPD</td>
<td>703</td>
</tr>
<tr>
<td><em>Gail Dechman</em></td>
<td></td>
</tr>
<tr>
<td>I. Introduction</td>
<td>703</td>
</tr>
<tr>
<td>II. Secretion-Removal Techniques</td>
<td>704</td>
</tr>
<tr>
<td>III. Secretion-Mobilization Techniques</td>
<td>706</td>
</tr>
<tr>
<td>IV. Physiological Effects of Enhanced Secretion Clearance</td>
<td>709</td>
</tr>
<tr>
<td>V. Breathing Exercise</td>
<td>711</td>
</tr>
<tr>
<td>VI. Exercise</td>
<td>713</td>
</tr>
<tr>
<td>VII. Conclusion</td>
<td>723</td>
</tr>
<tr>
<td>References</td>
<td>724</td>
</tr>
<tr>
<td>32. Exercise in Stable COPD</td>
<td>731</td>
</tr>
<tr>
<td><em>Claudia Ferdinando Donner and Antonio Patessio</em></td>
<td></td>
</tr>
<tr>
<td>I. Introduction</td>
<td>731</td>
</tr>
</tbody>
</table>
II. Factors Limiting Exercise Tolerance 732
III. Therapeutic Strategies 736
IV. Conclusion 747
V. References 748

33. Respiratory Muscle Training in Chronic Obstructive Pulmonary Disease 759
Thomas L. Clanton and Philip T. Diaz

I. Introduction 759
II. Rationale for Respiratory Muscle Training in COPD 760
III. Unresolved Issues Related to Training Methods: A Review of the Literature 766
IV. Conclusions and Speculations 775
References 776

Part Seven INSTRUMENTAL TREATMENTS

34. Long-Term Oxygen Therapy in Stable COPD 781
Emmanuel Weitzenblum, Ari Chaouat, Romain Kessler, Roland Schott, and Monique Oswald

I. Arguments for LTOT in Hypoxemic COPD: The Beneficial Effects of LTOT 781
II. Indications of LTOT in COPD 792
III. Home Oxygen 798
References 807

35. Domiciliary Noninvasive Ventilatory Support 813
Stefano Nava and Paolo Navalesi

I. Introduction 813
II. What Determines the Prognosis in Advanced COPD? 814
III. What Causes CO₂ Retention in COPD Patients? 815
IV. Rationale for Using Long-Term Noninvasive Ventilation 817
V. Clinical Studies 822
VI. When Should NIMV Be Started? 831
VII. How to Set Domiciliary Ventilation 834
VIII. How to Follow the Patients at Home 839
IX. Conclusions 840
Acknowledgments 840
References 840
36. The Indications for and Management of Tracheostomy in COPD 849

Jean-Francois Muir and Antoine Cuvelier

I. Physiological Basis for Chronic Mechanical Ventilation 851
II. Results of HMVT in COPD 853
III. Indications for HMVT in COPD 859
IV. Methods 862
V. From the Hospital to Home 864
References 865

Part Eight  SURGERY

37. Management of the COPD Patient Undergoing Surgery 871

B. Dureuil

I. Introduction 871
II. Pathophysiology of Postoperative Respiratory Complications 872
III. COPD as a Patient-Related Risk Factor 874
IV. Preoperative Evaluation and Preparation 875
V. Preoperative Preparation of Stable COPD Patients 879
VI. Intraoperative Management 881
VII. Postoperative Care and Risk-Reduction Strategies 884
VIII. Conclusion 887
References 888

38. Lung Volume Reduction Surgery and Chronic Obstructive Pulmonary Disease 895

P. M. A. Calverley and M. Fournier

I. Introduction 895
II. Theoretical Considerations 896
III. Physiological and Clinical Effects of LVRS 898
IV. Surgical Aspects of LVRS 905
V. Assessing the Cost of LVRS 909
VI. The Future of LVRS 912
References 914

39. Lung Transplantation and COPD 921

E. P. Trulock

I. Background 921
II. Recipient Selection 923
III. Timing Transplantation 925
IV. Bridging to Transplantation 927
Part Nine PERSPECTIVES

40. New Treatments for COPD

Peter J. Barnes

I. Introduction
II. New Bronchodilators
III. Smoking Cessation
IV. Mediator Antagonists
V. New Anti-Inflammatory Treatments
VI. Protease Inhibitors
VII. Mucoregulators
VIII. Alveolar Repair
IX. Route of Delivery
X. Future Directions

References

Part Ten MANAGEMENT OF COPD THROUGH THE WORLD

41. Critical Comparison of Guidelines

Nicolas Roche and Gerard J. Huchon

I. Introduction
II. Areas of Concordance and Discrepancies between Guidelines
III. What is a "Good" Clinical Practice Guideline?
IV. Are Recommendations on COPD "Good" Guidelines? Lessons from Experiences in Asthma
V. How Could COPD Guidelines be Improved?
VI. What are the Main Unanswered Questions?

References

42. Epidemiology and Management of COPD in Russia

A. G. Chuchalin and S. N. Avdeev

I. History
II. Morbidity and Mortality
III. Smoking
IV. Occupational Factors
V. Air Pollution
VI. Genetics 993
VII. Consequences of the Catastrophe at Chernobyl 994
VIII. Climatic Conditions 997
IX. Management 999
    References 1003

43. Epidemiology and Management of Stable COPD in Africa 1007
    N. Ait-Khaled, P. Chaulet, D. Enarson, and K. Slama
    I. Epidemiology 1007
    II. Management of Stable COPD in Africa 1018
    III. Conclusion 1026
        Acknowledgment 1026
        References 1026

44. Chronic Obstructive Pulmonary Disease in Latin America 1031
    Alvaro Undurraga, Patrick) Gonzalez, and Bartolome Celli
    I. Introduction 1031
    II. Latin America: The Facts 1031
    III. COPD in Latin America 1033
    IV. Some Etiopathogenic Factors of COPD 1035
    V. Latin American COPD Consensus 1040
    VI. Final Comments 1040
    References 1041

45. The Point of View of the WHO on Chronic Obstructive Pulmonary Disease 1045
    Nikolai Khaltaev
    I. Introduction 1045
    II. Definition and Classification 1046
    III. Epidemiology 1047
    IV. Risk Factors 1053
    V. Conclusion 1054
    References 1055

Index 1059